<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00264693</url>
  </required_header>
  <id_info>
    <org_study_id>LMWHplus 3</org_study_id>
    <secondary_id>Ethikkommission Luzern 542</secondary_id>
    <secondary_id>KSL 2006-1H</secondary_id>
    <nct_id>NCT00264693</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function</brief_title>
  <official_title>Pharmacokinetics of Dalteparin in Patients With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <brief_summary>
    <textblock>
      Low molecular weight heparins (LMWH) have been shown to be at least as efficient and safe as
      unfractioned heparin (UFH) in prophylaxis and treatment of venous thromboembolic events and
      in therapy of acute cardiovascular diseases. LMWH are widely used as safe replacement of oral
      anticoagulation with vitamin K antagonists (VKA).

      Due to their pharmacokinetic characteristics, LMWH tend to accumulate in patients with
      impaired renal function. Official guidelines recommend therefore to use LMWH controlled by
      Anti-Xa levels or to use UFH instead of LMWH to provide full therapeutic anticoagulation
      therapy in patients with severe renal insufficiency.

      Although dosage recommendations have been proposed for enoxaparin in patients with renal
      impairment based on several studies, these data cannot be applied to other LMWH directly due
      to different pharmacokinetic properties of each drug.

      The present study aims to clarify the pharmacokinetics of dalteparin in patients with renal
      insufficiency, especially addressing the question of accumulation after multiple doses and
      including patients with severe renal insufficiency and derive a safe and suitable concept for
      using dalteparin in patients with impaired renal function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Actual">96</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>P - A</arm_group_label>
    <description>Prophylactic Dosage, GFR &gt;= 60 mL/min/1.73m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P - B</arm_group_label>
    <description>Prophylactic Dosage, GFR 30-59 mL/min/1.73m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P - C</arm_group_label>
    <description>Prophylactic Dosage, GFR &lt; 30 mL/min/1.73m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P - CAPD</arm_group_label>
    <description>Prophylactic Dosage, CAPD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T - A</arm_group_label>
    <description>Therapeutic Dosage, GFR &gt;= 60 mL/min/1.73m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T - B</arm_group_label>
    <description>Therapeutic Dosage, GFR 30-59 mL/min/1.73m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T - C</arm_group_label>
    <description>Therapeutic Dosage, GFR &lt; 30 mL/min/1.73m^2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T - CAPD</arm_group_label>
    <description>Therapeutic Dosage, CAPD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of a medical and surcigal department with all levels of renal function who needs
        Dalteparin for prophylaxis or therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient starting with dalteparin for prophylaxis OR therapy by order of the treating
             physician (after having evaluated clinical indication and contraindications).

          -  Renal function normal OR impaired with or without dialysis therapy according to open
             study groups

          -  Age &gt;= 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy / Lactation

          -  Dalteparin or other LMWH already in use for &gt; 1 day, unless just in use during
             hemodialysis

          -  Anti-Xa level before first application of dalteparin &gt; 0.3 U / ml

          -  Participation in another study

          -  Anuria OR glomerular filtration rate &lt; 10 ml/min without dialysis

          -  Patient on intensive care unit (ICU)

          -  Cardiovascular unstable patient or probable need for a quick stop of anticoagulation
             (e.g. emergency surgery)

          -  Patient with a disease whose estimated life expectancy is &lt; 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirmin Schmid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luzerner Kantonsspital, Hematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas G Fischer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Luzerner Kantonsspital, Nephrology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Walter A Wuillemin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Luzerner Kantonsspital, Hematology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <state>LU</state>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ksl.ch/standorte/luzern/kliniken/medizin/haematologie.html</url>
    <description>Luzerner Kantonsspital, Hematology</description>
  </link>
  <link>
    <url>http://www.ksl.ch/standorte/luzern/kliniken/medizin/nephrologie.html</url>
    <description>Luzerner Kantonsspital, Nephrology</description>
  </link>
  <link>
    <url>http://www.pirmin-schmid.ch</url>
    <description>Pirmin Schmid</description>
  </link>
  <reference>
    <citation>Schmid P, Fischer AG, Wuillemin WA. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly. 2009 Aug 8;139(31-32):438-52. doi: smw-11284. Review.</citation>
    <PMID>19685350</PMID>
  </reference>
  <results_reference>
    <citation>Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009 Apr;7(4):552-8. doi: 10.1111/j.1538-7836.2009.03292.x. Epub 2009 Jan 19.</citation>
    <PMID>19175499</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost. 2009 Oct;7(10):1629-32. doi: 10.1111/j.1538-7836.2009.03556.x. Epub 2009 Jul 17.</citation>
    <PMID>19624460</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Prospective observational cohort study of bioaccumulation of dalteparin at a prophylactic dose in patients with peritoneal dialysis. J Thromb Haemost. 2010 Apr;8(4):850-2. doi: 10.1111/j.1538-7836.2010.03749.x. Epub 2010 Jan 17.</citation>
    <PMID>20088934</PMID>
  </results_reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2005</study_first_submitted>
  <study_first_submitted_qc>December 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2005</study_first_posted>
  <last_update_submitted>January 25, 2010</last_update_submitted>
  <last_update_submitted_qc>January 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>W.A. Wuillemin, MD PhD</name_title>
    <organization>Head, Division of Hematology and Hematology Central Laboratory, Kantonsspital Luzern, Luzern, Switzerland</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

